These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions. Denton CP; Humbert M; Rubin L; Black CM Ann Rheum Dis; 2006 Oct; 65(10):1336-40. PubMed ID: 16793845 [TBL] [Abstract][Full Text] [Related]
3. Bosentan for severe pulmonary arterial hypertension related to systemic sclerosis with interstitial lung disease. Ahmadi-Simab K; Hellmich B; Gross WL Eur J Clin Invest; 2006 Sep; 36 Suppl 3():44-8. PubMed ID: 16919010 [TBL] [Abstract][Full Text] [Related]
4. Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil. Launay D; Sitbon O; Le Pavec J; Savale L; Tchérakian C; Yaïci A; Achouh L; Parent F; Jais X; Simonneau G; Humbert M Rheumatology (Oxford); 2010 Mar; 49(3):490-500. PubMed ID: 20015974 [TBL] [Abstract][Full Text] [Related]
5. [Two-years therapy with bosentan of pulmonary arterial hypertension related to connective tissue diseases]. Marotta H; Montisci R; Tiso F; Pontarollo S; Rizzo M; Tona F; Iliceto S; Cozzi F Reumatismo; 2007; 59(4):299-303. PubMed ID: 18157286 [TBL] [Abstract][Full Text] [Related]
6. Bosentan therapy for pulmonary arterial hypertension. Rubin LJ; Badesch DB; Barst RJ; Galie N; Black CM; Keogh A; Pulido T; Frost A; Roux S; Leconte I; Landzberg M; Simonneau G N Engl J Med; 2002 Mar; 346(12):896-903. PubMed ID: 11907289 [TBL] [Abstract][Full Text] [Related]
7. [Pulmonary arterial hypertension in connective tissue disease]. Cottin V Rev Mal Respir; 2006 Sep; 23(4 Suppl):13S61-72. PubMed ID: 17057632 [TBL] [Abstract][Full Text] [Related]
8. Effects of bosentan on the skin lesions: an observational study from a single center in Japan. Funauchi M; Kishimoto K; Shimazu H; Nagare Y; Hino S; Yano T; Kinoshita K Rheumatol Int; 2009 May; 29(7):769-75. PubMed ID: 19037604 [TBL] [Abstract][Full Text] [Related]
9. Bosentan for the treatment of pulmonary arterial hypertension associated with congenital heart defects. Sitbon O; Beghetti M; Petit J; Iserin L; Humbert M; Gressin V; Simonneau G Eur J Clin Invest; 2006 Sep; 36 Suppl 3():25-31. PubMed ID: 16919007 [TBL] [Abstract][Full Text] [Related]
10. First experience with an oral combination therapy using bosentan and sildenafil for pulmonary arterial hypertension. Lunze K; Gilbert N; Mebus S; Miera O; Fehske W; Uhlemann F; Mühler EG; Ewert P; Lange PE; Berger F; Schulze-Neick I Eur J Clin Invest; 2006 Sep; 36 Suppl 3():32-8. PubMed ID: 16919008 [TBL] [Abstract][Full Text] [Related]
11. Effect of the oral endothelin antagonist bosentan on the clinical, exercise, and haemodynamic status of patients with pulmonary arterial hypertension related to congenital heart disease. Apostolopoulou SC; Manginas A; Cokkinos DV; Rammos S Heart; 2005 Nov; 91(11):1447-52. PubMed ID: 15761050 [TBL] [Abstract][Full Text] [Related]
12. Effect of bosentan on plasma markers of endothelial cell activity in patients with secondary pulmonary hypertension related to connective tissue diseases. Cella G; Vianello F; Cozzi F; Marotta H; Tona F; Saggiorato G; Iqbal O; Fareed J J Rheumatol; 2009 Apr; 36(4):760-7. PubMed ID: 19208592 [TBL] [Abstract][Full Text] [Related]
13. Long-term oral bosentan treatment in patients with pulmonary arterial hypertension related to congenital heart disease: a 2-year study. Apostolopoulou SC; Manginas A; Cokkinos DV; Rammos S Heart; 2007 Mar; 93(3):350-4. PubMed ID: 16980516 [TBL] [Abstract][Full Text] [Related]